Disc Medicine, Inc. (IRON) Stock News

Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and the firm is preparing a class action lawsuit to recover investor losses.

A securities class action lawsuit has been filed against AeroVironment, Inc. (AVAV) alleging the company made false and misleading statements regarding competition for U.S. Space Force contracts (SCAR and SCN programs). Investors who purchased securities between June 25, 2025 and March 10, 2026 may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing materially misleading business information. The investigation was triggered by an FDA Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, which caused the stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused the stock to plummet 22%. The Rosen Law Firm is now pursuing a class action lawsuit on behalf of shareholders who suffered losses, alleging the company issued materially misleading business information.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and investors who suffered losses are encouraged to join a prospective class action lawsuit.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing materially misleading business information. The investigation was triggered by an FDA Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, which caused the stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, that rejected the company's bitopertin drug application due to insufficient evidence. The rejection caused Disc Medicine's stock to plummet 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), TruBridge (TBRG), and PennyMac Financial Services (PFSI) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% on February 13, 2026, following an FDA Complete Response Letter rejecting its bitopertin program NDA. Investors who suffered losses are encouraged to join prospective class action lawsuits.

The Rosen Law Firm is investigating potential securities claims against multiple companies. Disc Medicine (IRON) received an FDA Complete Response Letter on its bitopertin program, causing a 22% stock price decline on February 13, 2026. The firm is also pursuing class action lawsuits against DNOW Inc. and Badger Meter, Inc. on behalf of affected shareholders.

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), TruBridge (TBRG), and Graphic Packaging Holding Company (GPK) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% following an FDA Complete Response Letter on its bitopertin program in February 2026.

Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and the firm is preparing a class action lawsuit to recover investor losses.

Rosen Law Firm is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) following the FDA's rejection of the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused the stock to plummet 22%. Investors who suffered losses are encouraged to join a class action lawsuit.

Bernstein Liebhard LLP has announced shareholder class action lawsuits against AeroVironment, Calix, and Zoetis. The lawsuits allege that the companies made materially false and misleading statements regarding their business operations, growth prospects, and financial stability, resulting in artificially inflated stock prices and significant investor losses.

Quarterly production of 3.4M wmt, sales of 3.5M dmt, revenues of $415M and EBITDA of $114M 1 DRPF project commissioning advancing as planned, with initial production tests successfully completed in March 2026 and production of commercially saleable product expected by the end of calendar Q2 2026 The previously announced acquisition of Rana Gruber, a proven high-purity iron ore producer in Norway, closed in April 2026 Announced the framework for future shareholder returns MONTRÉAL , May 27, 2026 /CNW/ - SYDNEY, May 28, 2026 - Champion Iron Limited (ASX: CIA) (TSX: CIA ) (OTCQX: CIAFF ) ("Champion" or the "Company") reports operational and financial results for its financial fourth quarter ended March 31, 2026. Champion's CEO, Mr. David Cataford, said, "This year marks the tenth anniversary of Champion's acquisition of Bloom Lake mine in April 2016, a defining milestone that laid the foundation for our long-term vision. Supported by an engaged workforce, the successful execution of multiple growth projects, and the recent acquisition of Rana Gruber, Champion continues to distinguish itself with customers worldwide as a leading supplier of high-purity iron ore. Beyond our operational achievements, we are proud to create lasting value for all stakeholders through strong partnerships with governments, local communities and First Nations. Although we are near the completion of a multi-year growth capital investment cycle at Bloom Lake, our focus is to protect our financial liquidities in response to the volatile macroeconomic environment and rising fuel and freight prices. Looking forward, our revised dividend policy will align our shareholder returns with our Company's financial capacity." Conference Call Details Champion will host a conference call and webcast on May 28, 2026, at 9:00 AM (Montréal time) / 11:00 PM (Sydney time) to discuss the results of the fourth quarter

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. The firm is preparing a class action lawsuit to recover investor losses.

Five Iron Golf opened its first Texas location in Fort Worth's Near Southside district, celebrating with tournament-week specials tied to the Charles Schwab Challenge at Colonial Country Club. The 10,000-square-foot venue features 12 Trackman simulators, a full-service bar, and entertainment amenities. Special offers include complimentary simulator time for anyone named Charles and appetizers for tournament attendees.

Five Iron Golf launched its third annual Women's Golf Month campaign throughout June 2026 in partnership with Golf Digest, offering free golf on Wednesdays, $5 first-month memberships, and women-focused social events across participating locations. The initiative aims to make golf more accessible and welcoming to women, building on momentum from previous years where thousands of women joined lessons, leagues, and memberships.

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. The firm is preparing a class action lawsuit to recover investor losses.

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The news triggered a 22% stock price decline. Investors who suffered losses are encouraged to join a prospective class action lawsuit.